Group 1 - The China Securities Regulatory Commission has confirmed the overseas issuance and listing of Hansi Aitai, which is preparing for a listing in Hong Kong [1] - Hansi Aitai plans to issue no more than 21,069,700 overseas listed ordinary shares and list on the Hong Kong Stock Exchange [2] - As of November 18, 2024, Hansi Aitai has developed a pipeline of 10 candidate drugs, including core products HX009 and HX044 [5] Group 2 - Hansi Aitai is a biotechnology company focused on the research and development of immunotherapy for cancer and autoimmune diseases, with core business areas including structural biology, translational medicine, and clinical development [5] - The company currently has no revenue, with net losses of 25.12 million, 84.62 million, and 43.13 million for the years 2022, 2023, and the first half of 2024, respectively [5]
第215家拟赴港上市企业完成备案
Sou Hu Cai Jing·2025-11-14 06:26